Angela Wittelsberger, Ph.D., scientific officer at the Innovative Medicines Initiative (IMI), is mostly involved in the planning and organisation of the early stages of new IMI projects, notably the interaction with industry partners and definition of new call topics, and communication and dissemination activities around new call topics and projects. She oversees in particular the activities of the IMI New Drugs for Bad Bugs (ND4BB) and vaccine programmes, including the recently launched Ebola+ programme. Angela holds a ‘Diplom’ (M.S.) in Chemistry from the University of Heidelberg, Germany, a DEA Multinational de Chimie Moleculaire de l’Ecole Polytechnique de Palaiseau, France, and a Ph.D. from the University of Lausanne, Switzerland. She spent 7 years in Boston, USA, where she held a faculty position first at Harvard Medical School, later at Tufts University School of Medicine. Back in Europe, she managed early innovation projects at Ablynx, a Belgian biotech company developing single-domain antibodies. She joined IMI in May 2012.